Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518696 | 0.84 | BCHE (0.65) | BCHEGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL12011335 | 0.84 | BCHE (0.65) | BCHEGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL14524626 | 0.84 | BCHE (0.65) | BCHEGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL30587413 | 0.83 | BCHE (0.72) | BCHEGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL12155343 | 0.83 | BCHE (0.77) | BCHEGAAKMT2AALDH1A1MAPK1 | |
| SCHEMBL30587417 | 0.83 | BCHE (0.72) | BCHEGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5047341 | 0.81 | BCHE (0.70) | BCHEGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL29833362 | 0.80 | BCHE (0.59) | BCHEGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL2560038 | 0.80 | BCHE (0.60) | BCHEGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5242683 | 0.80 | BCHE (0.60) | BCHEGAAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | disclosed |